| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| PTR-H5222 | Human | Human PTH1R / PTHR1 Protein, His Tag |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Teriparatide biosimilar (Intas Pharmaceuticals) | rhPTH (1-34) (Intas Pharmaceuticals) | Approved | Intas Biopharmaceuticals | Osteoporosis | Details | |||||
| Teriparatide biosimilar (STADA Arzneimittel AG) | rhPTH (1-34) (STADA Arzneimittel AG) | Approved | STADA Arzneimittel | teriparatide | ema | STADA Arzneimittel AG | 2017-01-11 | Osteoporosis | Details | |
| Teriparatide biosimilar (Virchow/Sun) | rhPTH (1-34) (Virchow/Sun) | Approved | Virchow Group, Sun Pharmaceutical | Osteoporosis | Details | |||||
| Teriparatide biosimilar (Gedeon Richter) | rhPTH (1-34) (Gedeon Richter) | Approved | Gedeon Richter | teriparatide | ema | Gedeon Richter Plc. | 2017-01-04 | Osteoporosis | Details | |
| Teriparatide biosimilar (USV) | Approved | USV | Osteoporosis | Details | ||||||
| Teriparatide biosimilar (Pfenex) | rhPTH (1-34) (Pfenex); PF-708 | Approved | Pfenex, NT Pharma, Alvogen | BONSITY | fda | ALVOGEN | 2019-10-04 | Osteoporosis | Details | |
| Teriparatide biosimilar (Zydus Cadila) | rhPTH (1-34) (Zydus Cadila) | Approved | Zydus cadila | Osteoporosis | Details | |||||
| Teriparatide acetate | AK-159; MN-10-T; hPTH (1-34) acet. H2O | Approved | USV, Ipsen, Asahi Kasei, Sanofi, Dong-A Pharmaceutical | Hypocalcaemia, Osteoporosis | Details | |||||
| Teriparatide biosimilar (Salubris) | Approved | Salubris | Recombinant Teriparatide for Injection | cfda | Osteoporosis in men, Postmenopausal osteoporosis | 2019-09-29 | Postmenopausal osteoporosis | Details | ||
| Teriparatide | hPTH-1-34; LY 333334; MN-10T | Approved | Lilly | FORTEO | fda | Osteoporosis | LILLY | 2002-11-26 | Osteoporosis | Details |
| Teriparatide (Amega Biotech) | rhPTH (1-34) (Amega Biotech) | Approved | Amega Biotech | Osteoporosis | Details | |||||
| Abaloparatide | ITM-058; BIM-44058; BA-058; BA-058-SC; BA-058-TD,BA058,BIM44058,ITM058 | Approved | Ipsen, Radius Health | TYMLOS | fda | Postmenopausal osteoporosis | RADIUS HEALTH INC | 2017-04-28 | Postmenopausal osteoporosis | Details |
| Teriparatide biosimilar (Biosidus) | rhPTH (1-34) (Biosidus) | Approved | Biosidus | Osteoporosis | Details | |||||
| Teriparatide biosimilar (CinnaGen) | rhPTH (1-34) (CinnaGen) | Approved | CinnaGen | Osteoporosis | Details | |||||
| Parathyroid hormone (Shire) | 423562; ALX-111; NPSP-795; NPSP-558; PTH (1-84); PTH 1-84; rhPTH (1-84); rhPTH-1-84; SB-423562; SHP-635; SHP-634 | Approved | Shire | parathyroid hormone (rDNA) | ema | Treatment of osteoporosis in postmenopausal women at high risk of fractures (see section 5.1). A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. |
NPS Pharma Holdings Limited | 2006-04-24 | Hypoparathyroidism, Osteoporosis | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ostabolin topical (Zelos) | Phase Ⅱ | Zelos Therapeutics | Psoriasis | Details | |
| Parathyroid hormone 7-34 (IGI) | PTH(7-34) | Preclinical | Teligent | Alopecia | Details |
| AJT-240 | AJT-240; SK-1403 | Phase Ⅲ | EA Pharma, JW pharmaceutical, Sanwa Kagaku Kenkyusho, Tasly Pharm | Hyperparathyroidism | Details |
| ZYPH-0907 | ZYPH-0907 | Phase Ⅰ | Zydus cadila | Osteoporosis | Details |
| Parathyroid hormone (1-34) gel (TG Therapeutics) | Phase Ⅰ | TG Therapeutics | Psoriasis | Details | |
| Teriparatide biosimilar (Stelis) | SBL-001,SBL001,SBL 001 | Phase Ⅰ | Stelis Biopharma | Osteoporosis | Details |
| Teriparatide liposomal cream (Manhattan Pharmaceuticals) | Phase Ⅱ | Boston University, TG Therapeutics | Psoriasis | Details | |
| BIM-44002 | BIM-44002 | Phase Ⅱ | Ipsen | Hypercalcemia | Details |
| Recombinant human parathyroid hormone (Green Cross) | Phase Ⅱ | Green Cross | Osteoporosis | Details | |
| Teriparatide biosimilar (Shanghai CAS Shenglongda Biotech) | Phase Ⅲ | Shanghai Zhongke Shenglongda Biotechnology | Postmenopausal osteoporosis | Details | |
| Recombinant parathyroid hormone (Beijing SL Pharmaceutical) | Phase Ⅱ | Beijing ShuangLu Pharmaceutical | Osteoporosis | Details | |
| Teriparatide biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical) | Phase Ⅰ | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Osteoporosis | Details | |
| Ostabolin (Zelos) | ZT-031 | Phase Ⅱ | Azelon Pharmaceuticals | Hip fracture, Menopausal symptoms, Postmenopausal osteoporosis, Osteoporosis | Details |
| Teriparatide (Critical Pharmaceuticals) | CP-046 | Phase Ⅰ | Critical Pharmaceuticals, University of Nottingham | Osteoporosis | Details |
| Recombinant parathyroid hormone (1-34) | Phase Ⅲ | Shanghai Zhongke Shenglongda Biotechnology | Postmenopausal osteoporosis | Details | |
| Parathyroid hormone 1-84 (Kerun Biopharmaceutical) | Phase Ⅱ | Kerun Biopharmaceutical, Heze Buchang Pharmaceutical | Osteoporosis | Details | |
| PCO-371 | PCO-371 | Phase Ⅰ | Chugai | Hypoparathyroidism | Details |
| KUR-115 | KUR-115 | Phase Ⅰ | Kuros Biosciences, Baxter | Bone disorders | Details |
| Recombinant human parathyroid hormone (Shenzhen Salubris Pharmaceuticals) | G56-W1; rhPTH(1-34) | Phase Ⅱ | Salubris | Osteoporosis | Details |
| Humanised anti-PTHrP antibody | Phase Ⅱ | Chugai | Hypercalcemia, Metastatic cancer | Details | |
| KUR-111 | KUR-111; I-0401 | Phase Ⅱ | Kuros Biosciences | Fractures | Details |
| BMD-1221 | BMD-1221 | Phase Not Specified | University of Arkansas System, BiologicsMD | Fractures | Details |
| Teriparatide biosimilar (Rhein Minapharm Biogenetics) | Phase Not Specified | Rhein Minapharm Biogenetics | Osteoporosis | Details | |
| Teriparatide biosimilar (National Institute of Dental and Craniofacial Research) | rhPTH (1-34) (National Institute of Dental and Craniofacial Research) | Phase Ⅲ | National Institute of Dental and Craniofacial Research | Primary hypothyroidism, DiGeorge Syndrome | Details |
| Teriparatide transdermal (Corium International) | Phase Ⅱ | Corium International | Osteoporosis | Details | |
| Parathyroid hormone analog (oral，Unigene/GlaxoSmithKline) | GSK-768974 | Phase Ⅱ | Unigene Laboratories | Postmenopausal osteoporosis | Details |
| Recombinant human parathyroid hormone 1-34 (Shanghai United Cell Biotech) | rhPTH (1-34) | Phase Ⅲ | Shanghai United Cell Biotechnology | Osteoporosis | Details |
| Teriparatide biosimilar (Dongguan Baolijian Bioengineer) | Phase Ⅲ | Dongguan baolijian biotech | Postmenopausal osteoporosis | Details | |
| T3-sulfate (Bracco SpA) | Phase Ⅱ | Bracco | Hypothyroidism | Details | |
| TransCon PTH | ACP-014 | Phase Ⅱ | Ascendis Pharma | Hypoparathyroidism | Details |
| Teriparatide biosimilar (United Cell Biotechnology) | IND Filing | Shanghai United Cell Biotechnology | Postmenopausal osteoporosis, Osteoporosis in men | Details | |
| Recombinant human parathyroid hormone (Beijing ShuangLu Pharmaceutical) | Phase Ⅱ | Beijing ShuangLu Pharmaceutical | Osteoporosis | Details | |
| Hemoparatide | hPTH-137 | Phase Ⅰ | Pharis Biotec | Psoriasis | Details |
| Teriparatide transdermal (Zosano Pharma) | B-104; B-106; TH-0229; ThPTH (1-34); ZP-PTH,B 104; B 106; TH 0229; ZP PTH,B104; B106; TH0229 | Phase Ⅱ | Zosano | Postmenopausal osteoporosis | Details |
| Teriparatide intranasal (Marina Biotech) | Phase Ⅱ | Marina Biotech | Osteoporosis | Details | |
| KUR-112 (Kuros Biosciences) | KUR-112; I-040302; TGplPTH1-34 | Phase Ⅰ | Kuros Biosciences | Bone cancer | Details |
| Teriparatide transdermal (TransPharma) | hPTH (1-34); ViaDerm-hPTH (1-34); ViaDor-hPTH (1-34) | Phase Ⅱ | TransPharma Medical, Lilly | Osteoporosis | Details |
| Teriparatide (Asubio Pharma) | SUN-E3001; CHS-13340 | Phase Ⅱ | Daiichi Sankyo, Chugai | Postmenopausal osteoporosis | Details |
| Teriparatide (Azelon Pharmaceuticals) | ZT-034 | Phase Ⅱ | Azelon Pharmaceuticals | Postmenopausal osteoporosis | Details |
| Recombinant Human Parathyroid Hormone (1-34), Shanghai Celgen Biopharmaceuticals | Phase Ⅱ | Shanghai Celgen Bio | Osteoporosis | Details | |
| Recombinant parathyroid hormone 1-34 (Uni-Bio Science Group) | rhPTH 1-34 (Uni-Bio Science Group);Uni-PH (1-34); Uni-rPH (1-34); Uni-PTH; UNI-PTH (1-34) | BLA Filing | Uni-Bio Science Group | Postmenopausal osteoporosis | Details |
| Teriparatide oral (Bone Medical) | BN-003,BN 003,BN003 | Phase Ⅱ | Botanix Pharmaceuticals | Osteoporosis | Details |
| KUR-113 | Fibrin-PTH; I-040202; KUR-113 | Phase Ⅱ | Kuros Biosciences | Fractures | Details |
This web search service is supported by Google Inc.
A-Z